PFS Data Show Carfilzomib Triplet Remains Inferior to VRd in Newly Diagnosed Myeloma
May 29, 2020 12:45am
By Jessica Skarzynski
In an interview with Targeted Oncology during the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma.
Simon J. Harrison, MBBS, PhD
The triplet combination of CD38-directed monoclonal antibody isatuximab, pomalidomide (Pomalyst), and dexamethasone prolonged progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma regardless of risk status, according to the findings from the phase III ICARIA-MM study that were presented at the 17th International Myeloma Workshop (IMW) Scientific Program.
In the analysis, high cytogenetic risk was defined as ≥1 for del(17p), t(4;14), or t(14;16) abnormalities and was performed by central laboratory at study entry. Cut-offs for del(17p), t(4;14), and t(14;16) were 50%, 30%, and 30%, respectively.
Overall response rate (ORR) benefit was maintained regardless of the high-risk cytogenetic cut-off definition used. Further, PFS benefit was observed in patients with standard- and high-risk cytogenetic risk. The median PFS for patients at high-risk who received the isatuximab regimen was 7.5 months versus 3.7 months in patients who received pomalidomide/dexamethasone alone (HR, 0.66; 95% CI, 0.30-1.28). In standard-risk patients, the median PFS was 11.6 months in the combination arm versus 7.4 months in the monotherapy arm.
In July 2019, the FDA accepted a biologics license application for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma, based on the overall ICARIA-MM data.
In an interview withTargeted Oncologyduring the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, hematologist and disease group lead: myeloma, Peter MacCallum Cancer Centre, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma.
TARGETED ONCOLOGY: What benefits were observed with the isatuximab triplet in the high-risk cytogenetic population?
Harrison: In the high-risk cytogenetic population, we saw a significant increase in response rateup to about 50% compared with 20%. The majority of that benefit was an increase in very good partial response (VGPR) rate, which was around 30% compared with around 3% in the control arm of the study. [This means that] isatuximab is increasing the depth of response as well as the ORR.
TARGETED ONCOLOGY: What do these outcomes mean for patients with high-risk cytogenetics?
Harrison: Patients with high-risk mutations across the board do less well, in terms of achieving a response but also in maintaining that response. The addition of isatuximab to pomalidomide and dexamethasone improves both response rate and duration of response. Therefore, a response that lasts for 5 minutes is not that helpful, whereas if you maintain that response for much longer, then clearly that’s an important marker to suggest that the overall survival (OS) will follow that when the analysis is complete in the future.
Patients with high-risk cytogenetic abnormalities benefit at least as much as standard-risk patients from the addition of isatuximab to pomalidomide/dexamethasone, so there is no reason not to offer that therapy to these patients. If you look at the odds ratio, in terms of the response, it seems that those patients with high-risk abnormalities benefit even more than the standard-risk patients.
It doesn’t overcome the overall negative impact of the high-risk abnormality, but it’s a step along the way to help the patients in that area of need achieve better outcomes.
TARGETED ONCOLOGY: What are some of the unique features of isatuximab?
Harrision: This molecule, isatuximab, uses a different epitope. It has a different adverse event profile, particularly in terms of reduced infusion reactions. Therefore, it has better tolerance for patients, so it offers a new alternative to daratumumab (Darzalex) in the clinic.
It may be because of the slightly different mechanism of action that it may be more effective in certain subgroups, particularly in those patients with high-risk cytogenetic abnormalities.
What else should be noted about the activity in those with high-risk abnormalities?
High-risk cytogenetics were defined in the study as del(17p), t(4;14), and t(14;16). The individual numbers of each of those abnormalities in the study was relatively small, so it’s hard to say what the overall impact of those abnormalities was across the study population. However, it seems to be that all of the high-risk populations benefitted similarly compared with the overall study population. The magnitude of the difference seems to be maintained.
One of the interesting findings from the study was that in patients with t(4;14), if they had a higher percentage of tumor cells expressing that cytogenetic abnormality, then those treated with isatuximab derived a greater benefit. However, again, the numbers are small and it is hard to say “Absolutely,” but it seems to be that high-risk patients seem to derive the same benefit as standard-risk patients across the board.
TARGETED ONCOLOGY: How could the use of subcutaneous daratumumab impact clinical practice?
Harrision: It seems to be subcutaneous antibodies across the board are associated with less toxicity while maintaining efficacy. So it’s simpler, easier to administer, and patients aren’t having the same reactions. Interesting thing though is that isatuximab doesn’t bind as strong as daratumumab and that seems to be the explanation for its fewer infusion-related reactions. Clearly there are ongoing studies looking at shorter duration infusions with isatuximab that appear to be safe. However, subcutaneous isatuximab will be investigated as well.
TARGETED ONCOLOGY: There has been a lot of focus during the 17th IMW Scientific Program on the high-risk population. Where does this leave the standard-risk population?
Harrison: The high-risk patients are a reasonable percentage of the population. Up to one-third of patients with myeloma have high-risk cytogenetic abnormalities; they have lagged behind in terms of their outcomes and it still remains an area of need, particularly the double-hit or the ultrahigh-risk patients with myeloma still have dismal outcomes.
On saying that, the biggest improvements have been in patients with standard risk. If we are ever going to cure anybody, then it’s going to be standard-risk patients. If we’re aiming for cure, then we still need to focus on the standard-risk patients and also not forget about the high-risk patients.
We probably need better studies designed to specifically accrue high-risk patients to address their specific needs, and it’s an area where we need more international collaboration with studies looking at that population to improve their outcomes.
Nolan E, VaillHarrison SJ, Richardson PG, Alegre A, et al. Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. Presented at: International Myeloma Workshop Scientific Program; September 12 to 16, 2019; Boston, MA. Abstract OAB-048.